Inspection Record

Central Admixture Pharmacy Services, Inc. — FDA 483 Findings

US FDAInspected 2015-07-10Published 2024-01-17 10 findingsDeviation, CAPA, and investigationOther quality systemMaterial and supplier controlEquipment and facilityLaboratory and QC controlsAseptic processing and sterility assuranceContamination control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed .

2Other quality system

Samples taken ofdrug products for determination ofconformance to written specifications are not representative.

3Material and supplier control

Each Jot ofcomponents was not appropriately identified as to its status in terms of being quarantined, approved or rejected .

4Equipment and facility

The operations relating to the processing and packing of penicillin are not perfom1ed in facilities sepa rate from those used for other drug products for human use.

5Laboratory and QC controls

Laboratory controls do not include the establishment ofscientifically sound and appropriate specifications designed to assure that components conform to appropriate standards ofidentity, strength, quality and purity.

6Equipment and facility

Buildings used in the manufacture, processing, packing, or holding ofa drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

7Other quality system

Written distribution procedures are not followed.

8Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and followed.

9Contamination control

Protective apparel is not worn as necessary to protect drug products fro m contamination.

10Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Central Admixture Pharmacy Services, Inc. company profile — full history US FDA documents, 2024 Go to Findings search